Search

Your search keyword '"Babjuk, Marek"' showing total 33 results

Search Constraints

Start Over You searched for: Author "Babjuk, Marek" Remove constraint Author: "Babjuk, Marek" Publication Year Range Last 3 years Remove constraint Publication Year Range: Last 3 years
33 results on '"Babjuk, Marek"'

Search Results

2. Preoperative Plasma Insulin-Like Growth Factor-I and Its Binding Proteins-Based Risk Stratification of Patients Treated With Radical Nephroureterectomy for Upper Tract Urothelial Carcinoma

3. En bloc resection of bladder tumour: the rebirth of past through reminiscence

6. Consistencies in Follow-up After Radical Cystectomy for Bladder Cancer: A Framework Based on Expert Practices Collaboratively Developed by the European Association of Urology Bladder Cancer Guideline Panels

7. Mapping European Association of Urology Guideline Practice Across Europe: An Audit of Androgen Deprivation Therapy Use Before Prostate Cancer Surgery in 6598 Cases in 187 Hospitals Across 31 European Countries

10. Comparative Outcomes of Primary Versus Recurrent High-risk Non–muscle-invasive and Primary Versus Secondary Muscle-invasive Bladder Cancer After Radical Cystectomy: Results from a Retrospective Multicenter Study

11. Preoperative plasma insulin-like growth factor-I and its binding proteins-based risk stratification of patients treated with radical nephroureterectomy for upper tract urothelial carcinoma

12. MP51-04 PROGNOSTIC VALUE OF INSULIN-LIKE GROWTH FACTOR-I AND ITS BINDING PROTEINS-BASED IN PATIENTS TREATED WITH RADICAL NEPHROURETERECTOMY FOR UPPER TRACT UROTHELIAL CARCINOMA

13. MP38-07 INTERLEUKIN-6 AND ITS SOLUBLE RECEPTOR AS BLOOD-BASED BIOMARKERS PREDICTING DISEASE OUTCOMES AFTER RADICAL NEPHROURETERECTOMY IN PATIENTS WITH UPPER TRACT UROTHELIAL CARCINOMA

14. MP38-06 PROGNOSTIC SIGNIFICANCE OF VCAM AND VEGF LEVELS PRIOR TO RADICAL NEPHROURETERECTOMY ON TREATMENT OUTCOMES

15. MP08-11 IMPACT OF PRE-SURGERY EGFR AND HER2 PLASMA LEVELS ON POST-SURGICAL OUTCOMES IN BLADDER CANCER PATIENTS RECEIVING RADICAL CYSTECTOMY

16. Clinical and molecular response to alpha1‐oleate treatment in patients with bladder cancer.

19. Bladder cancer therapy using a conformationally fluid tumoricidal peptide complex

20. Definitions, End Points, and Clinical Trial Designs for Bladder Cancer: Recommendations From the Society for Immunotherapy of Cancer and the International Bladder Cancer Group

21. How to follow the new EU Council recommendation and improve prostate cancer early detection: the Prostaforum 2022 declaration

22. Mapping European Association of Urology Guideline Practice Across Europe: An Audit of Androgen Deprivation Therapy Use Before Prostate Cancer Surgery in 6598 Cases in 187 Hospitals Across 31 European Countries

24. How to follow the new EU Council recommendation and improve prostate cancer early detection:the Prostaforum 2022 declaration

27. PD14-08 COMPARATIVE OUTCOMES OF PRIMARY AND RECURRENT HIGH GRADE NON-MUSCLE INVASIVE AND PRIMARY AND PROGRESSIVE MUSCLE-INVASIVE BLADDER CANCER AFTER RADICAL CYSTECTOMY: RESULTS FROM A RETROSPECTIVE MULTICENTER STUDY

28. Comparison of Clinicopathologic and Oncological Outcomes Between Transurethral En Bloc Resection and Conventional Transurethral Resection of Bladder Tumor: A Systematic Review, Meta-Analysis, and Network Meta-Analysis with Focus on Different Energy Sources

30. Diagnostic and prognostic value of placental growth factor serum concentration in clear cell renal cell carcinoma.

31. An international multicentre randomised controlled trial of en bloc resection of bladder tumour vs conventional transurethral resection of bladder tumour: first results of the en bloc resection of urothelium carcinoma of the bladder (EBRUC) II trial.

32. How to follow the new EU Council recommendation and improve prostate cancer early detection: the Prostaforum 2022 declaration.

33. Candida sojae: First report of a human infection.

Catalog

Books, media, physical & digital resources